Methylene Blue Reduces Aβ Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity

Promising results have emerged from a phase II clinical trial testing methylene blue (MB) as a potential therapeutic for Alzheimer disease (AD), where improvements in cognitive functions of AD patients after 6 months of MB administration have been reported. Despite these reports, no preclinical test...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Medina, David X., Caccamo, Antonella, Oddo, Salvatore
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2011
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2992595/
https://ncbi.nlm.nih.gov/pubmed/20731659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1750-3639.2010.00430.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky